Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | Journal of Pharmaceutical Policy and Practice

Fig. 2

From: Stakeholder driven development of a multi-criteria decision analysis tool for purchasing off-patent pharmaceuticals in Kuwait

Fig. 2

Graphic representation of the scoring for the price reduction of the alternatives versus the originator price. The original cut-off point determined in the workshop was − 47.5% meaning that all drugs offered at 52.5% of the originator price or below would receive a full score for the price criterion. The cut-off point was revised after the case study exercise to − 60%. Now, all prices at or below 40% of the originator price receive the full score. The scores between the originator price (Score = 0) and the full score follow a linear function

Back to article page